Drug Trial Radar · NCT07104344
Study of CM355 in Patients With Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5
Actual
Start
Sep 25, 2025
Primary completion
Jun 15, 2026
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to investigate the safety and efficacy of CM355 in patients with refractory SLE.
Conditions
- Systemic Lupus Erythematosus
Interventions
CM355Biological
CM355 injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- adverse events (AE)Time frame: Throughout the study,an average of about 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.